| Bioactivity | BMS-817399 is a potent, selective, and orally bioavailable CCR1 antagonist. BMS-817399 exhibits CCR1 binding affinity and chemotaxis inhibition potencies of 1 and 6 nM (IC50), respectively. BMS-817399 can be used for the research of rheumatoid arthritis[1]. |
| Invitro | In addition to MIP-1α (CCL3), BMS-817399 potently inhibits chemotaxis induced by other CCR1 ligands[1]. |
| Name | BMS-817399 |
| CAS | 1202400-18-7 |
| Formula | C23H36ClN3O4 |
| Molar Mass | 454.00 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Santella JB 3rd, et al. Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014;57(18):7550-7564. |
BMS-817399
CAS: 1202400-18-7 F: C23H36ClN3O4 W: 454.00
BMS-817399 is a potent, selective, and orally bioavailable CCR1 antagonist. BMS-817399 exhibits CCR1 binding affinity an
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.